Research programme: glutamate receptor antagonists - Astellas Pharma

Drug Profile

Research programme: glutamate receptor antagonists - Astellas Pharma

Alternative Names: AS1529122-FM; AS1655619-FM; YM 230888; YM 298198

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Benzimidazoles
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Japan (PO)
  • 02 Oct 2006 Data presented at the 232nd American Chemical Society National Meeting (232nd-ACS-2006) have been added to the Pain pharmacodynamics section
  • 25 May 2006 Preclinical trials in Pain in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top